Drug intelligence / Profile preview

Rejoint Gel

Development stage: Phase 1
Lead developer: National Taiwan University Hospital
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Intraarticular

Overview

**Rejoint Gel** is an investigational intra-articular mPEG-PLGA hydrogel being evaluated with platelet-rich plasma for unilateral knee osteoarthritis. It is administered as a local injectable gel intended to provide a physical polymer matrix that retains platelet-rich plasma within the joint and may prolong its local therapeutic activity. In the registered randomized, double-blind feasibility study NCT04519047, Rejoint Gel was evaluated at 150 mg/mL in a 2:1 mixture with platelet-rich plasma, administered twice over one month.

Other names: mPEG-PLGA hydrogel

Beyond the preview

Go deeper on Rejoint Gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rejoint Gel.

Explore the full profile